Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Common Equity (2017 - 2026)

DiaMedica Therapeutics filings provide 10 years of Common Equity readings, the most recent being $47.2 million for Q1 2026.

  • Quarterly Common Equity rose 39.11% to $47.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $47.2 million through Mar 2026, up 39.11% year-over-year, with the annual reading at $56.1 million for FY2025, 37.8% up from the prior year.
  • Common Equity hit $47.2 million in Q1 2026 for DiaMedica Therapeutics, down from $56.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $59.7 million in Q2 2023 and bottomed at $27.0 million in Q1 2023.
  • Average Common Equity over 5 years is $43.7 million, with a median of $46.3 million recorded in 2024.
  • The largest annual shift saw Common Equity surged 85.62% in 2022 before it tumbled 49.13% in 2025.
  • DiaMedica Therapeutics' Common Equity stood at $31.8 million in 2022, then surged by 60.42% to $51.1 million in 2023, then dropped by 20.25% to $40.7 million in 2024, then skyrocketed by 37.8% to $56.1 million in 2025, then dropped by 15.82% to $47.2 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Common Equity are $47.2 million (Q1 2026), $56.1 million (Q4 2025), and $51.6 million (Q3 2025).